He brings extensive leadership experience in digital health and diagnostics, having held senior roles at GE Healthcare, Roche Diagnostics, Doctor Care Anywhere, and Cyted Health.
Barclay holds an MBA from Cranfield School of Management and began his career as an Army Helicopter Pilot before moving into healthcare leadership. His expertise in driving commercial and operational growth will support Lucida Medical’s mission to deliver faster, more accurate, and more consistent prostate cancer diagnosis.
"Lucida Medical is tackling one of the most pressing challenges in healthcare, and I’m delighted to join the team," said Robin Barclay, COO of Lucida Medical. "By combining clinical insight with advanced AI, we have the opportunity to transform patient pathways and make prostate cancer diagnosis more efficient and reliable."
Dr. Antony Rix, CEO and Co Founder of Lucida Medical, added: "Robin’s track record in scaling healthcare businesses makes him an invaluable addition to our leadership team. His operational expertise will help us accelerate adoption of our technology and deliver meaningful impact for clinicians and patients."
Lucida Medical was founded in 2019 and develops CE certified software that analyses MRI scans and clinical data to deliver faster, more accurate, and more consistent diagnosis. Its flagship product, Prostate Intelligence (Pi), helps clinicians detect significant cancers earlier, prioritise patients more effectively, and reduce both waiting times and unnecessary biopsies. By streamlining workflows, shortening delays, and lowering costs, Pi aims to make prostate cancer diagnosis more efficient and reliable for hospitals, clinicians, and patients.
The team is delighted to welcome Robin Barclay on board and looks forward to working closely with him to achieve the next milestones in Lucida Medical’s growth and impact in prostate cancer diagnostics!
